We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
-8.4%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.07B
AUM Growth
-$732M
Cap. Flow
-$324M
Cap. Flow %
-7.96%
Top 10 Hldgs %
18.03%
Holding
679
New
46
Increased
261
Reduced
260
Closed
64

Top Buys

Rank Stock Value
1
NKE icon
Nike
NKE
+$31.9M
2
MCK icon
McKesson
MCK
+$27.5M
3
PG icon
Procter & Gamble
PG
+$27.1M
4
SBUX icon
Starbucks
SBUX
+$27M
5
NVDA icon
NVIDIA
NVDA
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 28.72%
2 Financials 13.85%
3 Technology 10.05%
4 Consumer Discretionary 8.55%
5 Consumer Staples 8.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DUK icon
376
Duke Energy
DUK
$102B
$1.42M 0.03%
19,766
+302
+2% +$21.9K
EEM icon
377
iShares MSCI Emerging Markets ETF
EEM
$28B
$1.41M 0.03%
42,916
-7,350
-15% -$260K
ITW icon
378
Illinois Tool Works
ITW
$81.4B
$1.4M 0.03%
16,990
-293
-2% -$25.6K
LVLT
379
DELISTED
Level 3 Communications Inc
LVLT
$1.39M 0.03%
31,751
+1,534
+5% +$73.9K
CLDX icon
380
Celldex Therapeutics
CLDX
$2.77B
$1.39M 0.03%
8,767
-2,233
-20% -$632K
AMAT icon
381
Applied Materials
AMAT
$426B
$1.37M 0.03%
93,559
-197,114
-68% -$3.29M
OREX
382
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.36M 0.03%
64,700
+1,200
+2% +$41.1K
TRIL
383
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.35M 0.03%
110,000
CPGX
384
DELISTED
COLUMBIA PIPELINE GROUP IN COM STK (DE)
CPGX
$1.35M 0.03%
+73,957
New +$1.93M
INTU icon
385
Intuit
INTU
$81.1B
$1.35M 0.03%
15,186
-202,922
-93% -$19.7M
SRPT icon
386
Sarepta Therapeutics
SRPT
$1.66B
$1.34M 0.03%
41,800
+1,800
+5% +$61.1K
SYY icon
387
Sysco
SYY
$39.7B
$1.33M 0.03%
34,058
+1,772
+5% +$67.6K
CAH icon
388
Cardinal Health
CAH
$53.4B
$1.32M 0.03%
17,224
-78,237
-82% -$6.54M
TCON
389
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$1.32M 0.03%
677
+52
+8% +$122K
RSG icon
390
Republic Services
RSG
$66.7B
$1.32M 0.03%
31,985
-4,656
-13% -$192K
NLY icon
391
Annaly Capital Management
NLY
$16.9B
$1.3M 0.03%
32,952
+4,363
+15% +$174K
NEE icon
392
NextEra Energy
NEE
$187B
$1.3M 0.03%
53,248
-17,336
-25% -$441K
NEM icon
393
Newmont
NEM
$98.2B
$1.3M 0.03%
80,696
+66,829
+482% +$1.2M
SO icon
394
Southern Company
SO
$110B
$1.29M 0.03%
28,879
+5,204
+22% +$228K
DYAX
395
DELISTED
DYAX CORPORATION
DYAX
$1.29M 0.03%
+67,600
New +$1.61M
JCI icon
396
Johnson Controls International
JCI
$87.5B
$1.29M 0.03%
29,785
+2,268
+8% +$105K
ATRA icon
397
Atara Biotherapeutics
ATRA
$71.2M
$1.28M 0.03%
1,628
+1,028
+171% +$1.25M
AZO icon
398
AutoZone
AZO
$48.3B
$1.27M 0.03%
1,760
-10,197
-85% -$7.22M
EFX icon
399
Equifax
EFX
$20.3B
$1.26M 0.03%
12,939
-3,727
-22% -$370K
MDXG icon
400
MiMedx Group
MDXG
$626M
$1.24M 0.03%
+128,000
New +$1.35M

Similar funds

Candriam SCA's Q3 2015 Portfolio in Review

As of Q3 2015, Candriam SCA held 679 positions worth $4.07B, down 15% from $4.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Candriam SCA withdrew a net $324M in Q3 2015, closing 64 positions and reducing 260 holdings. Its most notable exit was Alphabet (Google) Class C, an estimated $109M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 29% a quarter earlier, followed by Financials and Technology.

Against the trend, Candriam SCA opened a new position in Masco worth $14.9M.

  • Candriam SCA's largest Q3 2015 buy was Masco: 593,671 shares worth $14.9M.
  • Candriam SCA added most to Nike in Q3 2015, an estimated $31.9M increase.
  • Candriam SCA's biggest Q3 2015 reduction was iShares US Real Estate ETF, cutting an estimated $31.3M.
  • Candriam SCA fully exited Alphabet (Google) Class C in Q3 2015, selling an estimated $109M.
  • Candriam SCA's ten largest holdings make up 18% of its $4.07B portfolio in Q3 2015.
  • Candriam SCA opened 46 new positions and closed 64 in Q3 2015.
  • Candriam SCA's portfolio value fell 15% quarter-over-quarter to $4.07B.

Based on Candriam SCA's 13F filing for Q3 2015, filed 19 Oct 2015.